ArticleJTO clinical and research reports2021
First-in-Human Segmental Esophageal Reconstruction Using a Bioengineered Mesenchymal Stromal Cell-Seeded Implant.
Article in JTO clinical and research reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Esophagus engineering tackles function.Nature biotechnology · 2026Article
- Functional integration of an autologous engineered esophagus in a large-animal model.Nature biotechnology · 2026Article
- Decellularization Protocols for Esophagus Bioengineering: A Systematic Review.Bioengineering (Basel, Switzerland) · 2025Review
- Advances in Functional Scaffolds for Bone and Joint Surgery.Journal of functional biomaterials · 2025Article
- Eosinophilic esophagitis drives tissue fibroblast regenerative programs toward pathologic dysfunction.The Journal of allergy and clinical immunology · 2025Article
- Nanofibrous Scaffolds' Ability to Induce Mesenchymal Stem Cell Differentiation for Soft Tissue Regenerative Applications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- ASO Author Reflections: Resolving Postoperative Cough in Patients with Esophageal Cancer: The Brave Challenge of Sisyphus's Endless Cycle.Annals of surgical oncology · 2024Article
- Article
- Low molecular weight heparin decreases pro-coagulant activity in clinical MSC products.Cytotherapy · 2024Article
- Regenerative medicine: current research and perspective in pediatric surgery.Pediatric surgery international · 2023Review
- Current status and clinical applications of tissue engineering of the gastrointestinal tract: a systematized narrative review.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Esophageal regeneration following surgical implantation of a tissue engineered esophageal implant in a pediatric model.NPJ Regenerative medicine · 2022Article
- Development and Prospect of Esophageal Tissue Engineering.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
introductionResection and reconstruction of the esophagus remains fraught with morbidity and mortality. Recently, data from a porcine reconstruction model revealed that segmental esophageal reconstruction using an autologous mesenchymal stromal cell-seeded polyurethane graft (Cellspan esophageal implant [CEI]) can facilitate esophageal regrowth and regeneration. To this end, a patient requiring a full circumferential esophageal segmental reconstruction after a complex multiorgan tumor resection was approved for an investigational treatment under the Food and Drug Administration Expanded Access Use (Investigational New Drug 17402).
methodsAutologous adipose-derived mesenchymal stromal cells (Ad-MSCs) were isolated from the Emergency Investigational New Drug patient approximately 4 weeks before surgery from an adipose tissue biopsy specimen. The Ad-MSCs were grown and expanded under current Good Manufacturing Practice manufacturing conditions. The cells were then seeded onto a polyurethane fiber mesh scaffold (Cellspan scaffold) and cultured in a custom bioreactor to manufacture the final CEI graft. The cell-seeded scaffold was then shipped to the surgical site for surgical implantation. After removal of a tumor mass and a full circumferential 4 cm segment of the esophagus that was invaded by the tumor, the CEI was implanted by suturing the tubular CEI graft to both ends of the remaining native esophagus using end-to-end anastomosis.
resultsIn this case report, we found that a clinical-grade, tissue-engineered esophageal graft can be used for segmental esophageal reconstruction in a human patient. This report reveals that the graft supports regeneration of the esophageal conduit. Histologic analysis of the tissue postmortem, 7.5 months after the implantation procedure, revealed complete luminal epithelialization and partial esophageal tissue regeneration.
conclusionsAutologous Ad-MSC seeded onto a tubular CEI tissue-engineered graft stimulates tissue regeneration following implantation after a full circumferential esophageal resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.